Xanitos
Executives
14Board of Directors
3Xanitos Management Team
14 Team Members
Xanitos has 14 executives. Xanitos's current President, Chief Operating Officer is Michael A Bailey.
Name | Work History | Title | Status |
|---|---|---|---|
Michael A Bailey | President, Chief Operating Officer | Current | |
Name | Michael A Bailey | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | President, Chief Operating Officer | ||||
Status | Current |
This profile has not been claimed.
Highlight your management team’s expertise.
Xanitos Board of Directors
3 Board of directors
Xanitos has 3 board of directors, including Chris Grant.
Name | Firm | Work History | Other Seats |
|---|---|---|---|
Chris Grant | Chris is Senior Vice President and Managing Director of Kaiser Permanente's venture capital and corporate development group. He oversees Kaiser Permanente's venture investment strategy which is designed to support the company's healthcare mission while generating venture capital rates of return. Additionally, he oversees corporate development and merger and acquisitions company-wide. Chris is a Director or has observation rights to the board of numerous portfolio companies. Prior to the formation of the venture fund in 2000, Chris was responsible for creating, developing and managing a portfolio of new products and business lines for the organization. Before joining Kaiser Permanente in 1995, Chris held several positions on the Business Development and Financial Management Team of Rockwell International Corp. Additionally, Chris serves on the Board of Trustees of the Public School District and two charitable funds. Chris has a Bachelor&rsquo | Xanitos | |
David Schulte | Xanitos | ||
Michael Gross | Mr. Gross is Managing Director at Beringea, LLC and is responsible for investment sourcing, deal execution and portfolio management, with a focus on healthcare, technology enabled services, and sustainability. He joined the Board of Directors for Delphinus Medical Technologies in 2010. Within the Beringea portfolio of companies, he serves on the boards of Molecular Imaging, InTouch Health, Intervention Insights, Xanitos, Freeosk, and Fiber By-Products, and is a board observer for MedVantx. Previous portfolio companies include Pioneer Surgical Technology (acquired by RTI Biologics), Relume Technology (acquired by Revolution Lighting), and Ecosynthetix (TSX: ECO). Prior to joining Beringea, Mr. Gross was vice president of investment banking with P&M Corporate Finance as well as the investment banking group at Stout Risius Ross, Inc. He is a CFA charterholder and earned a B.A. in Finance from Michigan State University. | Xanitos |
Name | Chris Grant | David Schulte | Michael Gross |
|---|---|---|---|
Firm | |||
Work History | Chris is Senior Vice President and Managing Director of Kaiser Permanente's venture capital and corporate development group. He oversees Kaiser Permanente's venture investment strategy which is designed to support the company's healthcare mission while generating venture capital rates of return. Additionally, he oversees corporate development and merger and acquisitions company-wide. Chris is a Director or has observation rights to the board of numerous portfolio companies. Prior to the formation of the venture fund in 2000, Chris was responsible for creating, developing and managing a portfolio of new products and business lines for the organization. Before joining Kaiser Permanente in 1995, Chris held several positions on the Business Development and Financial Management Team of Rockwell International Corp. Additionally, Chris serves on the Board of Trustees of the Public School District and two charitable funds. Chris has a Bachelor&rsquo | Mr. Gross is Managing Director at Beringea, LLC and is responsible for investment sourcing, deal execution and portfolio management, with a focus on healthcare, technology enabled services, and sustainability. He joined the Board of Directors for Delphinus Medical Technologies in 2010. Within the Beringea portfolio of companies, he serves on the boards of Molecular Imaging, InTouch Health, Intervention Insights, Xanitos, Freeosk, and Fiber By-Products, and is a board observer for MedVantx. Previous portfolio companies include Pioneer Surgical Technology (acquired by RTI Biologics), Relume Technology (acquired by Revolution Lighting), and Ecosynthetix (TSX: ECO). Prior to joining Beringea, Mr. Gross was vice president of investment banking with P&M Corporate Finance as well as the investment banking group at Stout Risius Ross, Inc. He is a CFA charterholder and earned a B.A. in Finance from Michigan State University. | |
Other Seats | Xanitos | Xanitos | Xanitos |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.